Differential effects of hormone therapy on serotonin, vascular function and mood in the KEEPS

Limor Raz, Mayo Clinic
Larry Hunter, Mayo Clinic
N. Maritza Dowling, University of Wisconsin
Whitney Wharton, Emory University
Carey Gleason, University of Wisconsin
Muthuvel Jayachandran, Mayo Clinic
Layne Anderson, Mayo Clinic
Sanjay Asthana, University of Wisconsin
Virginia Miller, Mayo Clinic

Journal Title: Climacteric  
Volume: Volume 19, Number 1  
Publisher: Taylor | 2016-01-02, Pages 49-59  
Type of Work: Article | Post-print: After Peer Review  
Publisher DOI: 10.3109/13697137.2015.1116504  
Permanent URL: https://pid.emory.edu/ark:/25593/rk8fj

Final published version: http://dx.doi.org/10.3109/13697137.2015.1116504

Copyright information:  
© 2015 International Menopause Society  
Accessed April 1, 2019 10:19 PM EDT
Abstract

Background—Serotonin (5-hydroxytryptamine, 5-HT) is modulated by sex steroid hormones and affects vascular function and mood. In the Kronos Early Estrogen Prevention Cognitive and Affective Ancillary Study (KEEPS-Cog), women randomized to oral conjugated equine estrogens (oCEE) showed greater benefit on affective mood states than women randomized to transdermal 17β-estradiol (tE2) or placebo (PL). This study examined the effect of these treatments on the platelet content of 5-HT as a surrogate measure of 5-HT synthesis and uptake in the brain.

Methods—The following were measured in a subset (n = 79) of women enrolled in KEEPS-Cog: 5-HT by ELISA, carotid intima-medial thickness (CIMT) by ultrasound, endothelial function by reactive hyperemia index (RHI), and self-reported symptoms of affective mood states by the Profile of Mood States (POMS) questionnaire.

Results—Mean platelet content of 5-HT increased by 107.0%, 84.5% and 39.8%, in tE2, oCEE and PL groups, respectively. Platelet 5-HT positively correlated with estrone in the oCEE group.
and with 17β-estradiol in the tE2 group. Platelet 5-HT showed a positive association with RHI, but not CIMT, in the PL and oCEE groups. Reduction in mood scores for depression-dejection and anger-hostility associated with elevations in platelet 5-HT only in the oCEE group (r = −0.5, p = 0.02).

**Conclusions**—Effects of oCEE compared to tE2 on RHI and mood may be related to mechanisms involving platelet, and perhaps neuronal, uptake and release of 5-HT and reflect conversion of estrone to bioavailable 17β-estradiol in platelets and the brain.

**Keywords**
conjugated equine estrogen; 17β-estradiol; 5-hydroxytryptamine; Kronos Early Estrogen Prevention Study; platelet

**Introduction**

Serotonin (5-hydroxytryptamine, 5-HT) is a monoamine that functions as a neurotransmitter in the brain and exerts complex effects on the cardiovascular system. Within the peripheral circulation, a portion of 5-HT is inactivated by the liver, but the majority is taken-up, transported and stored in dense granules of platelets. 5-HT released from activated platelets binds to serotonergic receptors on platelets initiating platelet aggregation, the vascular endothelium inducing the release of vasoactive substances and the vascular smooth muscle initiating either relaxation or contraction depending on the concentration and the anatomical origin of the blood vessel.

In the brain, 5-HT is synthesized in serotonergic neurons from L-tryptophan by tryptophan hydroxylase. Most 5-HT in the brain is stored within synaptic vesicles of the raphe nuclei. 17β-estradiol increases mRNA of serotonin reuptake transporter (SERT) as well as the density of SERT-binding sites in the brains of experimental animals. The 5-HT transporter on human platelets is identical to the brain 5-HT transporter; platelet 5-HT content has been used as a surrogate marker of its synthesis and uptake in the brain.

Evidence supports an association between depressive mood disturbances, low brain 5-HT, risk of cardiovascular disease and adverse cardiovascular events. Incidence of depression is greater in women compared to men, and following menopause, depressive symptoms and mood disturbances increase in some women. Estrogens exert antidepressant effects, in part, by modulating synthesis and uptake of 5-HT. Estrogens affect vasomotor tone by increasing release of endothelium-derived vasodilatory substances and reducing platelet aggregation and secretion. Therefore, menopausal hormone therapy (MHT) may reduce depressive symptoms directly by modulating 5-HT levels in the brain and indirectly by modulating cerebral vascular reactivity.

Effects of MHT on mood and the relationship to 5-HT in the systemic circulation and cardiovascular risk remains unexplored in menopausal women. Several studies report a positive association between platelet 5-HT turnover and plasma estrogen levels in menopausal women, but none have related these to cardiovascular risk and only one compared two different formulations of estrogen. The objective of this study was to compare
the association of two MHT formulations (oral conjugated equine estrogens and transdermal 17β-estradiol) with serum and platelet 5-HT levels in healthy, recently menopausal women and the relationship of these levels with progression of cardiovascular disease as defined by carotid intima-media thickness (CIMT), and with endothelial function measured by pulse volume digital tonometry. In addition, using platelet 5-HT as a surrogate for 5-HT in the brain, the association between platelet 5-HT and mood also was examined.

Methods

Participants

Participants (n = 79) were a subset of Caucasian women enrolled in the Kronos Early Estrogen Prevention Cognitive and Affective Ancillary Study (KEEPS-Cog) at Mayo Clinic, Rochester, MN (Figure 1). The KEEPS-Cog, an ancillary study to the parent Kronos Early Estrogen Prevention Study (KEEPS), was designed to test the "critical period hypothesis" that MHT started early in menopause would improve mood and maintain cognition 18. The KEEPS was a multicenter, randomized, double-blinded, placebo-controlled clinical trial enrolling healthy women between July 2005-June 2008 without a prior history of cardiovascular or cerebrovascular disease (NCT00154180) 19. Briefly, inclusion criteria were: women between 42-58 years of age who experienced natural menopause and were within 6 months to 3 years of menopause. Menopause was defined by FSH level ≥ 35 ng/ml and estradiol levels <25 pg/ml. A normal mammogram within 1 year of randomization was required. Exclusion criteria were: coronary arterial calcification score of >50 Agatston Units, smoking over 10 cigarettes per day, BMI >35 kg/m², history of cardiovascular disease, low density lipoprotein cholesterol >190 mg/dL, triglycerides >400 mg/dL, blood glucose >126 mg/dL, uncontrolled hypertension (systolic blood pressure >150 mmHg and/or diastolic blood pressure >95 mm Hg), current or recent (6 months) use of cholesterol lowering medications (statins, fibrate, or >500 mg/day niacin), follicle stimulating hormone (FSH) level ≤5 ng/mL, estrogen levels ≥ 25 pg/mL 19, and symptoms consistent with clinical depression (based on Beck's Depression Inventory 2nd edition score of ≥28/63 or reporting suicidal ideation as assessed by the Beck’s Depression Inventory or scoring ≤ 22/30 on the Mini-Mental State Exam) 20, 21.

Study design

Women were randomized for 48 months to either: oral conjugated equine estrogens (o-CEE; Premarin, 0.45 mg/day); transdermal 17β-estradiol (t-E2; skin patch, Climera, 50 μg/day; or placebo pills and patch (PL). Women randomized to active treatments also received oral progesterone (Prometrium; micronized progesterone, 200 mg/day) for 12 days each month for the duration of the study to protect the uterus. Each participant underwent a medical examination, including body morphometrics and standard blood chemistries prior to randomization 19, 22.

Standard protocol approvals, registrations, and patient consents

This study was approved by the Mayo Clinic Institutional Review Board (IRB protocol #2241). All participants gave written informed consent.
Profile of Mood States (POMS) survey

POMS is a self-report survey composed of 65 psychological distress measurements, each ranked on a five-point Likert scale organized by mood inventories or subscales as depression-dejection, anger-hostility, tension-anxiety, confusion-bewilderment, fatigue-inertia and vigor-activity. POMS was completed prior to randomization (baseline; BL) and after 48 months (48m) of treatment (Figure 1). In the KEEPS-Cog study, there were significant effects of MHT on depression-dejection, anger-hostility and tension-anxiety and thus, these moods became the focus of the present evaluations with 5-HT.

Blood sampling and chemistries

Fasting venous blood was collected at BL and 48m after randomization into tubes containing hirudin plus soybean trypsin inhibitor or sodium citrate anticoagulants and without anticoagulant for serum. Serum to be used for measurement of 5-HT was stored at −80°C until analysis. All samples were batched and assayed at the conclusion of the study. Serum 5-HT was quantified by ELISA (GenWay Biotech Inc., San Diego, CA). Inter- and intra-assay coefficients of variation were 7.6% (n=6) and 11% (n=5), respectively.

Serum total cholesterol, low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C), triglycerides and fasting blood glucose (FBG) were measured by Kronos Science Laboratories (Phoenix, AZ). Estrone (E1), 17β-estradiol (E2), and testosterone (T) were measured using high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) and sex hormone binding globulin (SHBG) was measured by two-site chemiluminescent immunoassay, using the Immulite 2000 at the Mayo Clinic Department of Laboratory Medicine and Pathology (Rochester, MN).

Platelet lysates

Washed platelets were prepared as described previously. Absence of leukocytes contamination in the platelet preparation was verified by Coulter counter prior to storage of the platelets at −80°C. To prepare the lysate, the isolated stored platelets were thawed in a 37°C water bath and placed in 200 μl of lysis buffer [(#0103004-L; RayBioTech, Norcross, GA) containing 5 mM TRIS, 0.5% TRITON X100, and protease inhibitor cocktail (#P8340, Sigma, St. Louis, MO), pH 7.4]. This solution was passed through a 26-gauge needle at least 3 times, sonicated and then centrifuged at 10,000g for 5min to remove lysed membrane particulates and organelles. The total protein concentration in the supernatant was measured by bicinchoninic acid assay (BCA kit #23225, Pierce, Rockford, IL) and 5-HT was analyzed by ELISA according to manufacturer’s instructions (GenWay Biotech, Inc., San Diego, CA). Inter- and intra-assay coefficients of variation were 4.5% (n = 11) at BL and 12.0% (n = 9) at 48m. Although serum and platelets were collected from all 79 participants, total volumes of materials in some cases were insufficient to perform all of the assays in all of the participants. The number of participants from whom platelet assays were performed is provided in Figure 1.

Carotid intima-medial thickness (CIMT)

CIMT, the primary outcome of KEEPS, was measured by B-mode ultrasound.
**Endothelial function**

Endothelial function was measured using a peripheral tonometer to detect changes in pulse volume digital tonometry during reactive hyperemia (EndoPAT, model 2000; Itamar Medical, Ltd., Caesarea, Israel)\(^{27,28}\). The Reactive Hyperemia Index (RHI) was calculated by dedicated software in the system computer.

**Statistical analysis**

Baseline and follow-up participant data was evaluated for normality using histograms and box plots for graphical visualization of data points. Conventional cardiovascular risk factors (with the exception of participant count and percentage of smokers) met normality. Participant characteristics are shown as mean and standard deviation (mean \(\pm\) SD) for continuous variables and as percentages for categorical variables. Hormones were treated as continuous variables. Mean change in mood scores were calculated as the difference in scores at 48m from BL. Sample size calculations were performed at 80% power (\(\alpha=0.05\)).

The effect size required to achieve statistical significance of MHT on platelet 5-HT levels at 48m is 8 participants. Linear regression was used to test the associations between serum and platelet lysate 5-HT concentrations and POMS outcomes. Correlation coefficients (r) and corresponding p-values were calculated for the simple linear regression model. One-way analysis of variance (ANOVA) was performed to compare the means of the three treatment groups, followed by Dunn’s and Holm-Sidak post-hoc tests to control Type I error rate. The familywise error rate (FWER) was set to 0.05.

**Results**

**General characteristics**

In this sub-set of KEEPS-Cog participants, the average age at enrollment was 52 years. Other demographics and clinical characteristics at BL and 48m are presented in Table 1. At BL, conventional cardiovascular risk factors were within normative ranges. At 48m, waist circumference was significantly larger in the PL group compared to tE2 group (\(p = 0.01\)) and triglyceride levels were significantly higher in the oCEE group compared to tE2 group (\(p = 0.02\)). The number of participants meeting criteria for metabolic syndrome\(^{29}\) at 48m was similar among groups: PL: 1; tE2: 2; oCEE: 2.

At 48m, compared to PL, serum concentrations of E1 were significantly higher in the oCEE group (\(p = 0.001\)); E2 levels were significantly higher in tE2 group (\(p < 0.0001\)). Serum concentrations of SHBG were significantly higher in oCEE group as compared to tE2 and PL groups (\(p = 0.001\); Table 2). Serum total testosterone did not differ among groups.

**Effects of MHT on serum and platelet 5-HT**

At BL, serum 5-HT levels showed large variability and did not differ among treatment assignments (\(p = 0.98\)) averaging 77.0 \(\pm\) 8.7 ng/mL (mean \(\pm\) SD) for all participants. Serum levels of 5-HT did not change significantly from BL nor differ significantly among groups after 48m of treatment: 75.1 \(\pm\) 7.0, 78.4 \(\pm\) 8.4, 79.5 \(\pm\) 9.2 ng/mL for PL, tE2 and oCEE, respectively (\(p = 0.16\); Figure 2).
Platelet count did not vary significantly over the course of the study or among groups at follow-up (Table 1). At BL, platelet content of 5-HT did not differ among groups (p = 0.80): 294.5 ± 218.3 (n=24), 355.6 ± 283.1 (n=21) and 252.2 ±157.0 (n=17) pg/mg of protein in the PL, tE2 and oCEE groups, respectively. After 48m of treatment, mean platelet 5-HT content increased by 39.8% (to 411.2 ± 204.5 pg/mg protein) in the PL group and by 107% (to 529.8 ± 236.7 pg/mg protein) and 84.5% (to 465.4 ± 278.9 pg/mg protein) in the tE2 and oCEE groups, respectively (Figure 2). The change in mean platelet content between the tE2 and BL group was statistically significant (p = 0.02). There was a positive association between serum and platelet 5-HT only in the tE2 group (p = 0.04; data not shown).

There were nominal positive associations between E2 and E1 and platelet levels of 5-HT in the tE2 (r = 0.34, p = 0.04) and oCEE (r = 0.34, p = 0.05; Figure 3) groups, respectively, and between testosterone and platelet 5-HT levels in the PL group at 48m (R=0.37, p=0.04). Associations of SHBG with platelet 5-HT concentrations were negative and statistically significant for tE2 (r = −0.43, p = 0.01) but showed a positive trend for oCEE (r = 0.41, p = 0.07; Figure 3). There was a nominally significant positive association between E2/E1 ratio with platelet 5-HT (r = 0.38, p = 0.04) in the tE2 group. The range in E2 concentrations in the oCEE group was not broad enough to establish meaningful evaluation of these ratios in this group.

**Platelet 5-HT and vascular assessments**

There were no significant associations between either serum or platelet 5-HT and changes in CIMT (data not shown). However, platelet 5-HT content was positively and significantly associated with higher RHI in women of the PL and oCEE groups at 48m (r = 0.42, p = 0.03; r = 0.57, p = 0.02, respectively; Figure 4).

**Platelet 5-HT and relationship to mood**

There were no statistically significant differences in overall POMS scores or individual components of POMS among group assignments at baseline. Compared to BL, at 48 months, overall negative mood states as measured by the POMS scale increased (worsened) in the PL group by 10.5% but significantly decreased (improved) by 4.7% and 7% in the tE2 and oCEE groups, respectively (Table 3). Changes in scores for individual components of mood followed this general pattern with reduction of symptoms for depression-dejection, anger-hostility and tension-anxiety being greater in both the oCEE and tE2 groups compared to PL (p = 0.001). Reduction in scores in the oCEE group were greater for anger-hostility and tension-anxiety than in the tE2 group (p = 0.001). Lower scores for depression-dejection and anger-hostility significantly correlated with increases in platelet content of 5-HT only in women of the oCEE group (Figure 5). Serum testosterone levels did not correlated with anger-hostility scores in any group (data not shown).

**Discussion**

Results of this study provide evidence that oral conjugated equine estrogens and transdermal 17β-estradiol differentially affect content of serotonin in platelets and components of mood in healthy menopausal women. At menopause, risk increases for developing mood
Serotonin may contribute to both processes as a neurotransmitter in the brain and as a vasoactive amine that promotes endothelium-dependent relaxation but causes contraction of vascular smooth muscle and promotes platelet aggregation. Evidence suggests a relationship between depression and cardiovascular disease. However, the relationship of MHT and 5-HT to both processes is controversial, in part, due to regulation and expression of 5-HT receptor subtypes, differences in measurement of 5-HT and differences in dose and type of estrogen treatments used in various studies. The present study compared two MHT products which are used clinically for relief of menopausal symptoms and represent doses consistent with clinical guidelines.

Results of the present study are consistent with other observations that MHT correlates with circulating (platelet) 5-HT levels and turnover and improves mood and reduces depressive symptoms. The progesterone component of MHT may be involved in these effects, as progesterone to upregulates the 5-HT(2A) receptor binding potential and serum levels of progesterone correlated with increased metabolism of 5-HT in the brain. In addition, our results provide insight into differences in effects of oral CEE, which contain multiple metabolites of 17β-estradiol, the primary of which is estrone as compared to transdermal 17β-estradiol. In addition, variation in serum concentrations of SHBG between treatment groups indicates direct effects of the oral product on the liver similar to what is reported for effects on pro-inflammatory cytokines such as C-reactive protein.

Serum concentrations of 5-HT reflect, in part, amine released from activated platelets in coagulated blood. Levels of serum 5-HT measured in the present study are consistent with those measured by others in postmenopausal women with and without MHT. However, serum levels do not account for incomplete activation or release of 5-HT from the platelets as indicated by the lack of positive correlation between serum and platelet content of 5-HT in the PL and oCEE groups. Thus, serum levels of 5-HT could underestimate effects of the treatment on synthesis and uptake of the amine.

**Differential effects of MHT on platelet 5-HT and vascular function**

The platelet count did not differ significantly among the groups after 48 months of treatment. Both hormone treatments tended to increase 5-HT content of platelets with the major estrogenic compound in each treatment having a positive association with platelet content of 5-HT. The E2/E1 ratio may reflect total biologically available estrogens in menopausal women. The platelet content of 5-HT was positively associated with the E2/E1 ratio only in the tE2 group, suggesting that the relative concentration of estrogen metabolites may affect synthesis, uptake, release and degradation of the amine.

Increases in SHBG may partially explain the differences in platelet content of 5-HT between oCEE and tE2 groups. Binding affinity of sex steroids to SHBG is T>E2>E1 thus reducing bio-available E2. Conversion of E1 to E2 at the cellular level would increase site-specific of E2. Results of the present study are consistent with those of others showing that oCEE treatment increases serum SHBG and extend observations to indicate a negative
association between serum SHBG and platelet 5-HT levels in the tE2 group but a positive correlation in the oCEE group.

Uptake of 5-HT from the blood by platelets, endothelium and nerve terminals may be cardioprotective, but with onset of cardiovascular disease, the sensitivity of platelets to 5-HT uptake and clearance by the endothelium may diminish\(^1\),\(^{45}\). RHI, as a measure of vasodilatation, increased with increasing platelet content of 5-HT in the oCEE group. 5-HT released from platelets can augment release of endothelium-derived relaxing factors though activation of receptors on the endothelium\(^46\). The absence of an association with tE2 may reflect the relationship between platelet and serum levels 5-HT in this group and not the others. Furthermore, 5-HT is one of many vasoactive and mitogenic products released from activated platelets\(^47\) and the measure of individual components may not represent the collective effect on vascular remodeling.

CIMT increases with age and the increases in CIMT were comparable among treatment groups\(^48\) which reflects, in part, the low cardiovascular risk status of women at the time of enrollment, the collective effect of other vasoactive and mitogenic products that are released by activated platelets\(^47\), the genomic interactions with treatment\(^49\), as well as the short duration of the study. It remains to be seen if changes in CIMT would be different among treatment assignments after women completed study drugs. Additional, follow-up studies of KEEPS participants would provide insight into temporal relationships of MHT use and vascular remodeling.

**Differential effects of MHT on platelet 5-HT and mood**

Results of the present study are consistent with other reports of MHT improving mood and a sense of well-being in menopausal women with absent or mild depressive symptoms\(^50\). The changes in mood scores are consistent with clinical meaningful improvement in mood based on the standard established for clinical trials examining pain control\(^51\). An expert panel recommended that a change of one standard error of the mean or half of a standard deviation should be considered clinically significant. According to these guidelines, the o-CEE group demonstrated clinically meaningful change at 48m on the depression-dejection and tension-anxiety subscales (Table 3).

Results of the present study also are consistent with other reports of positive correlations between plasma estrone and 17\(\beta\)-estradiol on platelet 5-HT levels in non-depressed postmenopausal women\(^15\). However, only in the oCEE group were scores for depression-dejection and anger-hostility related to platelet content of 5-HT. This difference between oCEE and tE2 treatments most likely reflects different pharmacokinetics and physiological mechanisms of action of estrogens metabolites associated with the two formulations. The oral preparation of conjugated equine estrogens (CEE) contains E1, as well as estrone sulfate and 17\(\beta\)-estradiol sulfate, which have lower binding affinity for the estrogen receptor than 17\(\beta\)-estradiol. Therefore, ligand-bound estrogen receptors will affect modulation of the serotonergic system differently at multiple control points, including increasing enzymatic expression of tryptophan hydroxylase-2, the rate limiting enzyme for 5-HT synthesis, and release and uptake through increased 5-HT receptor and transporter expression\(^5\),\(^{52}\),\(^{53}\). E1 can be converted to 17\(\beta\)-estradiol and as such may serve as a circulating storage form of the
hormone. Therefore, circulating levels of E2 may not be reflective of conversion of E1 to E2 at the tissue level in the oCEE group.

Limitations

This study has several limitations. First, the analysis utilized only change from baseline at one time point (48 months) and does not take into account longitudinal variability. Second, concentrations of 5-HT in platelet lysate may not reflect that released following agonist activation of platelets as might occur during reactive hyperemia. Third, 5-HT measured in platelets is only an estimate of synthesis and transporter activity in the brain. Fourth, effects of MHT on mood reporting may be biased as POMS is a profile of immediate mood state and may be influenced by personal transient circumstances. Fifth, 5-HT is a monoamine derived from the amino acid tryptophan, the levels of which are affected by food intake. Oral intake of 5-HT cannot pass into the serotonergic pathway of CNS, unless it is metabolized to 5-hydroxytryptophan (5-HTP), although this factor may be limited as samples were collected after an overnight fast. In addition, the active smokers were in the tE2 group and it is unclear how this cardiovascular risk factor would affect 5-HT metabolism. Finally, KEEPS-Cog participants were a homogenous population of healthy Caucasian women and therefore, results may not generalize to a population of women with various cardiovascular risk factors.

Conclusion

The platelet content of 5-HT and its associations to E2/E1 ratio differ between oCEE and transdermal E2, suggesting that local concentrations of estrogen metabolites affect 5-HT uptake and synthesis. Although both oCEE and transdermal tE2 improved mood, mechanisms involving synthesis and activation of 5-HT transporters with neuronal activation may differ as higher platelet content of 5-HT, as a surrogate for synthesis and uptake, was associated with improved mood only in the oCEE group. It was not possible to identify a relationship between platelet 5-HT and vascular remodeling reflected by changes in CIMT. However, analysis of platelet 5-HT with a more dynamic and transient measure of cardiovascular function, for example, endothelial reactive hyperemia, provides insight into interactions among MHT, 5-HT, endothelial and platelet physiology. Additional studies are needed to determine how various formulations of MHT affect mood, 5-HT and cardiovascular risk relative to variants in genes encoding enzymes which metabolize E1 to E2 and their sulfonation and genes encoding estrogen receptors.

Acknowledgments

Study Funding: The Aurora Foundation to the Kronos Longevity Research Institute, NIH HL90639, NS066147, HD65987, AG029624, P50 AG033514, UL1 RR024150 and the Mayo Foundation. Study medications for KEEPS were supplied in part by Bayer Health Care and by Abbott Pharmaceuticals.

Additional Contributions: We gratefully acknowledge the dedicated efforts of all the investigators and staff at the KEEPS clinical centers, the KEEPS Data Coordinating Center at KLRI, study coordinator, Teresa G. Zais (deceased), and Robert D. Litwiller for technical assistance collecting the blood. Above all, we recognize and thank 1From the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and the NIH Roadmap for Medical Research. Contents of this paper are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH.
the KEEPS participants for their dedication and commitment to the programs of the Mayo Clinic Women’s Health Research Center.

References

18. Wharton W, Gleason CE, Miller VM, Asthana S. Rationale and design of the Kronos Early Estrogen Prevention Study (KEEPS) and the KEEPS cognitive and affective sub study (KEEPS Cog). Brain Res. 2013; 1514:12–7. [PubMed: 23603409]


Figure 1.
Flow chart defining the KEEPS-Cog cohort participating in this study. Total number of participants (n = 79) in whom sufficient serum and platelets were available for analysis is reported by treatment group in placebo (PL), transdermal (tE2) or oral (oCEE) estrogen preparations.
Figure 2.
Levels of 5-HT in serum (left panel) and platelet lysates (right panel) at baseline (BL) and after 48 months (48m) of treatment with placebo (PL), transdermal 17β estradiol (tE2) or oral conjugated equine estrogens (oCEE). Asterisk denotes statistical significant difference from BL (p = 0.002*).
Figure 3.
Correlations of serum estrone (E1), estradiol (E2), sex hormone binding globulin (SHBG) and testosterone (T) with platelet lysate levels of 5-HT in women receiving placebo (PL) and transdermal (tE2, 17β-estradiol; Climera, 50 μg/day) or oral (oCEE; Premarin, 0.45 mg/day) hormone preparations. Each dot represents an individual.
Figure 4.
Relationship between platelet 5-HT and endothelial function as measured by flow-mediated reactive hyperemia index (RHI) via pulse volume digital tonometry at 48m. Correlations are presented by treatment in placebo (PL, n = 21), transdermal (tE2, n = 14) and oral (oCEE, n = 13) groups. Each symbol represents data from an individual.
Figure 5.
Associations of peripheral platelet 5-HT levels (pg/mg protein) with components of mood by treatment group at 48m. A lower self-reported mood score represents improved mood. Consistent significant associations were found between increases in platelet 5-HT and decreases in scores for depression-dejection and anger-hostility (less depression-dejection and anger-hostility) in the oCEE group at follow up ($r = -0.52$, $p = 0.02$).
Table 1
Clinical characteristics of the subset of KEEPS-Cog participants at baseline (BL) and 48 months (48m) following randomization to treatment.

<table>
<thead>
<tr>
<th></th>
<th>Placebo (PL)</th>
<th>Transdermal (tE2)</th>
<th>Oral (oCEE)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>BL 48m</td>
<td>BL 48m</td>
<td>BL 48m</td>
</tr>
<tr>
<td>Number of participants</td>
<td>28 27</td>
<td>24</td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>52.7±0.3</td>
<td>57.2±2.0</td>
<td>52.8±0.6</td>
</tr>
<tr>
<td>Time past menopause (months)</td>
<td>16.0±1.7</td>
<td>64.0±8.5</td>
<td>17.1±1.9</td>
</tr>
<tr>
<td>Mean systolic blood pressure (mmHg)</td>
<td>120.9±13.3</td>
<td>121.0±14.7</td>
<td>118.6±15.8</td>
</tr>
<tr>
<td>Mean diastolic blood pressure (mmHg)</td>
<td>74.2±7.6</td>
<td>77.0±8.9</td>
<td>72.5±8.4</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>27.7±3.6</td>
<td>29.0±3.9</td>
<td>26.0±4.4</td>
</tr>
<tr>
<td>Waist circumference (cm)</td>
<td>86.2±2.1</td>
<td>93.0±10.0</td>
<td>83.0±2.5</td>
</tr>
<tr>
<td>Low-density lipoprotein (LDL, mg/dL)</td>
<td>136.9±7.0</td>
<td>117.0±29.1</td>
<td>125.2±6.4</td>
</tr>
<tr>
<td>High-density lipoprotein (HDL, mg/dL)</td>
<td>60.7±3.0</td>
<td>72.0±13.5</td>
<td>59.9±3.1</td>
</tr>
<tr>
<td>Triglycerides (mg/dL)</td>
<td>91.1±9.9</td>
<td>92.0±55.7</td>
<td>94.0±7.6</td>
</tr>
<tr>
<td>Fasting blood glucose (mg/dL)</td>
<td>93.6±1.6</td>
<td>81.0±6.3</td>
<td>95.0±1.3</td>
</tr>
<tr>
<td>Carotid intima medial thickness (CIMT;mm)</td>
<td>0.67±0.07</td>
<td>0.70±0.09</td>
<td>0.69±0.09</td>
</tr>
<tr>
<td>Reactive Hyperemia Index</td>
<td>2.4±0.9</td>
<td>2.6±0.7</td>
<td>2.4±0.7</td>
</tr>
<tr>
<td>Platelet count, citrate (10³/μL)</td>
<td>240.7±37.1</td>
<td>243.2±59.0</td>
<td>237.9±53.4</td>
</tr>
<tr>
<td>Smoking status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Never</td>
<td>21</td>
<td>17</td>
<td>15</td>
</tr>
<tr>
<td>Past</td>
<td>7</td>
<td>6</td>
<td>9</td>
</tr>
<tr>
<td>Current</td>
<td></td>
<td>4</td>
<td></td>
</tr>
</tbody>
</table>

Conventional cardiovascular (CV) risk factors measured at baseline and 48 months are reported as mean ± SD; the number of participants is reported as counts and smoking status is presented as percentage of counts (%). Statistical significance denoted as:

*PL vs. tE2 at 48 months, p=0.01;
**oCEE vs. tE2 at 48 months, p=0.02.
Table 2
Hormone concentrations in serum of KEEPS-Cog participants at 48 months.

<table>
<thead>
<tr>
<th>Hormone</th>
<th>PL (n = 23)</th>
<th>tE2 (n = 25)</th>
<th>oCEE (n = 20)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Estrone (E1) (pg/mL)</td>
<td>20±6.3</td>
<td>34±13.2</td>
<td>67±36.8 †††</td>
</tr>
<tr>
<td>Estradiol (E2) (pg/mL)</td>
<td>6.1±2.4</td>
<td>29±27.8 †</td>
<td>14±6.9</td>
</tr>
<tr>
<td>Testosterone (T) (ng/dL)</td>
<td>23±16.0</td>
<td>24.2±11.6</td>
<td>27.7±11.7</td>
</tr>
<tr>
<td>Sex Hormone Binding Globulin (SHBG) (nmol/L)</td>
<td>50.3±27.4</td>
<td>58.6±24.5</td>
<td>106.6±47.6 ††</td>
</tr>
</tbody>
</table>

††† compared to PL, p=0.001;
† compared to PL, p<0.0001;
†† compared to PL and tE2, p=0.001.
### Table 3
Baseline and mean changes in mood parameters of KEEPS-Cog participants following menopausal hormone treatment.

<table>
<thead>
<tr>
<th>Mood Parameters</th>
<th>PL</th>
<th>tE2</th>
<th>oCEE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean (SD)</td>
<td>Mean (SD)</td>
<td>Mean (SD)</td>
</tr>
<tr>
<td></td>
<td>BL</td>
<td>Change</td>
<td>BL</td>
</tr>
<tr>
<td>Profile of Mood States</td>
<td>37.7±14.4</td>
<td>4.1±5.9</td>
<td>42.8±12.2</td>
</tr>
<tr>
<td>(POMS)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depression-Dejection</td>
<td>3.0±3.7</td>
<td>1.8±0.6</td>
<td>4.4±3.8</td>
</tr>
<tr>
<td>Anger-Hostility</td>
<td>2.9±3.3</td>
<td>0.9±4.2</td>
<td>3.8±3.6</td>
</tr>
<tr>
<td>Tension-Anxiety</td>
<td>4.4±4.1</td>
<td>−0.5±0.7</td>
<td>6.0±3.8</td>
</tr>
</tbody>
</table>

Self-reported Profile of Mood States (POMS) parameters of KEEPS participants by treatment group, presented as mean ± SD; mean change was calculated as the difference in scores at 48 months for PL (n=28), tE2 (n=27) and oCEE (n=21) groups from baseline. Statistical significance reported for mean change:

* tE2 and oCEE vs. PL, p = 0.001;
** tE2 and oCEE vs. PL, p = 0.02;
† oCEE vs. tE2, p = 0.03;
‡ oCEE vs. tE2, p = 0.001.